Protagonist Therapeutics Inc (PTGX NASDAQ) stock market data APIs
$46.0343
-0.03(-0.1%)
as of May 23, 2025
Try our APIs with
free plan!
Protagonist Therapeutics Inc Financial Data Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Prev. Close
46.0343
Open
46.0009
High
45.6511
Low
44.8509
52 wk Range
27-60.6
Market Cap
2 830 M
P/E Ratio
58.5385
Shares Outstanding
61 982 K
Revenue
208 M
EPS
-0.19
Beta
2.641
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Protagonist Therapeutics Inc data using free add-ons & libraries
Get Protagonist Therapeutics Inc Fundamental Data
{
"General": {
"Code": "PTGX",
"Type": "Common Stock",
"Name": "Protagonist Therapeutics Inc",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG002B63KM7",
"ISIN": null,
"CUSIP": null,
"CIK": "0001377121",
"EmployerIdNumber": "98-0505495",
"FiscalYearEnd": "December",
"IPODate": "2016-08-11",
"InternationalDomestic": "Domestic",
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": "Domestic",
"IsDelisted": false,
"Description": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycy..."
}
}Protagonist Therapeutics Inc Fundamental data includes:
- Net Revenue: 208 M
- EBITDA: 28 053 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: 0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Protagonist Therapeutics Inc News
New
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will p...
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands agains...
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demon...
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Most readers would already be aware that Protagonist Therapeutics' (NASDAQ:PTGX) stock increased significantly by 14% over the past three months. As most would know, fundamentals are what usually guid...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
